

## ASX RELEASE

---

23 August 2017

### Satipharm AG Patent Cooperation Treaty (PCT) Application Update

#### Highlights:

- **Patent Cooperation Treaty application submitted by Harvest One Cannabis Inc's Swiss-based subsidiary Satipharm AG in February 2017 has now been published**
- **PCT application covers the Gelpell-CBD product technology and will also cover cannabis-derived prescription drugs currently under clinical development by MMJ's 100%-owned subsidiary PhytoTech Therapeutics Limited**
- **Once granted, the patent will be equally owned by Satipharm AG and Gelpell AG**

**MMJ PhytoTech Limited (ASX: MMJ)** ("MMJ" or "the Company") is pleased to advise that the Patent Cooperation Treaty ("PCT") application submitted by Harvest One Cannabis Inc's ("Harvest One") Swiss-based subsidiary Satipharm AG ("Satipharm") in February 2017 has now been published. The Company maintains a shareholding interest of approximately 59% in Harvest One.

This comprehensive patent application is directed at Satipharm's proprietary Gelpell-CBD product technology, and covers oral formulations utilising both singular and/or a combination of cannabinoids. Once granted, the patent will be owned equally by Satipharm and its manufacturing partner Gelpell AG ("Gelpell") and will also cover, via an exclusive agreement, the cannabis-derived prescription drugs developed by MMJ's wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Limited ("PTL").

The unique Gelpell-CBD product technology enables flexibility in manufacturing a wide range of doses at various ratios of cannabinoids that can be used for multiple indications and personalised medicine.

In 2016, Gelpell granted Satipharm an exclusive license to develop and sell products using Gelpell's proprietary technology, for the treatment or prevention of any medical condition or disease in humans and animals and for food and dietary supplements ("Gelpell IP"). Under the terms of the licence, the parties agreed that all intellectual property generated under the licence will be jointly owned between Gelpell and Satipharm, but Satipharm will maintain exclusivity to any licenced intellectual property.

Satipharm has, in turn, granted PTL the exclusive rights to exploit the Gelpell IP in the worldwide pharmaceutical field (excluding Canada).

#### **MMJ PhytoTech's Managing Director, Andreas Gedeon, commented:**

"This patent progression is a key development for our research and development team, and reaffirms the Company's commitment to strengthening its intellectual property portfolio. We

## ASX RELEASE

remain focused on expanding our R&D capabilities and we look forward to providing further updates on this division in due course.”

– ENDS –

### **For media and investor inquiries please contact:**

**Andreas Gedeon**  
**Managing Director**  
**+1 (250) 713 6302**  
**agedeon@mmj.ca**

**Released through Sam Burns, Six Degrees Investor Relations, M: +61 400 164 067**



**Follow us on Twitter @MMJPhytoTechLtd**

<http://www.mmjphytotech.com.au>

### **About MMJ Phytotech Limited**

**MMJ Phytotech Limited (ASX: MMJ)** is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C\$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through its ~60% interest in TSX-V listed **Harvest One Cannabis Inc** (TSXV: HVST) and its 100% interest in Israeli research and development subsidiary, **PhytoTech Therapeutics Ltd**, both of which are strategically located in favourable jurisdictions with supportive regulatory frameworks in place.

### **About Harvest One Cannabis Inc.**

**Harvest One Cannabis Inc. (TSXV: HVST)** controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation licence, making Harvest One one of only a few companies globally with the capacity to commercially cultivate cannabis in a federally regulated environment.